Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

Published: Dec-2014 | Format: PDF | GlobalData | Number of pages: 48 | Code: MRS - 1780

Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body’s immune system attacks the lining of the joints causing an inflammatory response. RA is characterized by joint swelling, pain, and redness, which can cause bone and cartilage erosion, and joint deformity. The disease can lead to premature mortality, disability, and decreased quality of life.

GlobalData epidemiologists forecast an increase in the total prevalent cases of RA in the 8MM, from 12,901,398 total prevalent cases in 2013 to 14,896,291 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.55% over the forecast period. GlobalData epidemiologists also forecast an increase in the diagnosed prevalent cases of RA in the 10MM, from 7,328,399 diagnosed prevalent cases in 2013 to 8,518,398 diagnosed prevalent cases in 2023, at an AGR of 1.62% over the forecast period.

For this analysis, GlobalData epidemiologists used country-specific data from peer-reviewed journals to construct the 10-year epidemiological forecast for the total prevalent cases of RA in the 8MM. GlobalData epidemiologists built the forecast for the diagnosed prevalent cases of RA in the 10MM using a combination of country-specific primary and secondary sources. A major strength of GlobalData’s epidemiological analysis is the use of consistent disease definitions and uniform diagnostic criteria, thereby allowing for a meaningful comparison of the epidemiological characteristics of RA in the 10MM.

Scope

The Rheumatoid arthritis (RA) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for RA in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It also includes a 10-year epidemiological forecast for the total prevalent cases of RA, segmented by age (18 to =85 years) and sex in the eight major markets (8MM) (France, Germany, Italy, Spain, UK, Japan, China, and India). Additionally, this report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of RA in the 10MM. 
The RA epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global RA market.
Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RA therapeutics in each of the markets covered.

Table of Contents


1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 8

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 11
3.3.1 US 11
3.3.2 5EU 12
3.3.3 Japan 13
3.3.4 Australia 13
3.3.5 China 14
3.3.6 India 14
3.4 Forecast Methodology 14
3.4.1 Sources Used 17
3.4.2 Sources Not Used 21
3.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of RA 22
3.4.4 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA 26
3.5 Epidemiological Forecast for RA (2013-2023) 27
3.5.1 Total Prevalent Cases of RA 27
3.5.2 Age-Specific Total Prevalent Cases of RA 29
3.5.3 Sex-Specific Total Prevalent Cases of RA 31
3.5.4 Diagnosed Prevalent Cases of RA 33
3.5.5 Age-Standardized Diagnosed Prevalence of RA 35
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
3.6.2 Limitations of the Analysis 37
3.6.3 Strengths of the Analysis 38

4 Appendix 39
4.1 Bibliography 39
4.2 About the Authors 43
4.2.1 Epidemiologists 43
4.2.2 Reviewers 43
4.2.3 Global Director of Therapy Analysis and Epidemiology 44
4.2.4 Global Head of Healthcare 45
4.3 About GlobalData 46
4.4 About EpiCast 46
4.5 Disclaimer 47"

List of Tables

Table 1: Risk Factors and Comorbidities for RA 11
Table 2: 1987 ACR Diagnostic Criteria for RA 15
Table 3: 10MM, Sources of RA Prevalence Data 16
Table 4: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023 28
Table 5: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2013 30
Table 6: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2013 32
Table 7: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2013-2023 34"

List of Figures

Figure 1: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023 29
Figure 2: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2013 31
Figure 3: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2013 33
Figure 4: 10MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, 2013-2023 35
Figure 5: 10MM, Age-Standardized Prevalence of RA (%), Ages ≥18 Years, 2013 36

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3995 View Pricing